Volume 29, Number 3—March 2023
Dispatch
Tuberculosis Preventive Therapy among Persons Living with HIV, Uganda, 2016–2022
Table 2
Semiannual periods | Overall | Patient age |
Patient sex |
|||
---|---|---|---|---|---|---|
<15 y | >15 y | M | F | |||
2016 Oct–2017 Mar† |
881.1 (7,850/890,938) |
NA |
NA |
NA |
NA |
|
2017 Apr–2017 Sep‡ |
523.4 (5,198/993,070) |
465.6 (290/62,279) |
331.2 (3,083/930,791) |
642.0 (2,106/328,026) |
201.0 (1,267/630,451) |
|
2017 Oct–2018 Mar† |
860.1 (8,866/1,030,756) |
NA |
NA |
NA |
NA |
|
2018 Apr–2018 Sep‡ |
1,015.3 (11,186/1,101,716) |
1,633.7 (1,035/63,353) |
294.1 (3,054/1,038,363) |
547.9 (2,128/388,410) |
274.9 (1,961/713,306) |
|
2018 Oct–2019 Mar |
1,028.3 (11,284/1,097,366) |
1,553.2 (929/59,812) |
998.0 (10,355/1,037,554) |
1,694.1 (6,528/385,331) |
667.9 (4,756/712,035) |
|
2019 Apr–2019 Sep |
1,094.4 (12,566/1,148,258) |
1,607.6 (985/61,273) |
1,065.4 (11,581/1,086,985) |
1,774.4 (7,195/405,491) |
723.1 (5,371/742,767) |
|
2019 Oct–2020 Mar |
918.9 (11,037/1,201,166) |
1,182.6 (730/61,731) |
904.6 (10,307/1,139,435) |
1,489.6 (6,336/425,358) |
605.9 (4,701/775,808) |
|
2020 Apr–2020 Sep |
710.2 (8,650/1,218,006) |
756.6 (462/61,062) |
707.7 (8,188/1,156,944) |
1,148.3 (4,956/431,584) |
469.7 (3,694/786,422) |
|
2020 Oct–2021 Mar |
866.8 (10,747/1,239,829) |
1,144.3 (678/59,249) |
854.1 (10,083/1,180,580) |
1,356.2 (5,921/436,577) |
602.6 (4,840/803,252) |
|
2021 Apr–2021 Sep |
908.8 (11,511/1,266,588) |
1,175.1 (703/59,925) |
895.6 (10,808/1,206,763) |
1,388.7 (6,185/445,390) |
648.6 (5,326/821,198) |
|
2021 Oct–2022 Mar | 972.5 (12,483/1,283,662) | 1,416.5 (813/57,396) | 951.7 (11,670/1,226,266) | 1,504.8 (6,788/451,092) | 684.0 (5,695/832,570) |
*Values are no./100,000 population (actual number of notifications among PLHIV/total PLHIV population). Tuberculosis notification rate is defined as the number of registered new and relapsed TB cases with documented HIV-positive status during the reporting period divided by the total number of PLHIV currently receiving antiretroviral treatment at PEPFAR-supported sites in Uganda. NA, not applicable; PEPFAR, US President’s Emergency Plan for AIDS Relief. †Total number of tuberculosis cases disaggregated by age and sex were not available. ‡Disaggregated totals for age groups and sex do not equal the overall totals in periods 2 and 4 because of synchronization issues between DATIM (Uganda DATIM version 1.31 MER 2.5, updated January 4, 2021; https://ug.datim4u.org) and the national reporting system; only the sites in which disaggregated totals were consistent with the national reporting system were included.